e 4.38); lung: þ2.41% (95%CI: 2.40 e 2.43); and prostate: þ4.25% (95%CI: 4.24 e 4.27)). This represents 5,322 additional minority patients accessing definitive.CONCLUSIONS: We found that patients treated at MSH for breast, colon, NSLSC, and prostate cancer are significantly less likely to receive definitive treatment for their treatment-eligible disease compared to patients treated at non-MSHs. Equalizing facility-level access to definitive cancer treatment between MSHs and non-MSHs would reduce patient-level national racial/ethnic disparities.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.